Is Clinuvel Pharmaceuticals Limited (CLVLF) a Buy, Sell, or Hold?
OTC : CLVLF
Clinuvel Pharmaceuticals Limited
$6.1 USD
$0 (0.0%)
- Volume
- 1.5K
- Average Volume
- 159
- Market Capitalization
- $307.51M
- P/E Ratio
- 15.48
- Dividend Yield
- 0.50%
- Price Target
- Year High
- $8.60
- Year Low
- $6.10
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.08
- Current Ratio
- $14.64
Company Overview
OTC
Philippe Jacques Wolgen
Biotechnology
Healthcare
CLVLF
109
AU
USD
Liquidity Metrics
0.00
14.64
14.17
2.02
0.08
Sales & Valuation
$95.02M
5.27
2.03
12.65
0.80
Profitability
$0.72
$36.17M
33.79%
45.90%
13.29%
12.07%
P/E Metrics
15.48
-0.99
-0.99
Analyst Price Target & Rating
4/5
0 Analysts
%
Financial Health Scores
16.06
5/9
$243.43M
$269.59M
$20.67M
$91.52M
Key Metrics (TTM)
$471.34M
4.89
11.32
14.64
13.29%
11.07%
6.45%
7.90%
$8.51
39 days
Company Executives
| Name | Title |
|---|---|
| Azza Hamila | Head of Quality Assurance & Drug Safety |
| Dennis J. Wright | Chief Scientific Officer |
| Emilie Rodenburger | Director of Global Clinical Affairs |
| Linda Teng | Director of North American Operations |
| Philippe Jacques Wolgen | Chief Executive Officer, MD & Director |
| Lachlan Hay | Chief Operations Officer |
| Malcolm Bull | Head of Australian Operations & Investor Relations |
| Claire Newstead-Sinclair | Company Secretary |
| Peter Vaughan | Chief Financial Officer |
Poll Results
No votes yet today — be the first to share your view!
About Clinuvel Pharmaceuticals Limited (OTC:CLVLF) Stock
Clinuvel Pharmaceuticals Limited (CLVLF), an Australian biopharmaceutical firm established in Melbourne in 1987, specializes in the creation and global marketing of therapeutic solutions. Its primary focus is on patients suffering from genetic, metabolic, and severe, life-threatening conditions, with operations spanning Australia, Europe, the United States, Switzerland, and various international markets. The company's flagship product is SCENESSE, a systemic photoprotective medication. This drug is specifically designed to prevent light-induced damage in adult individuals diagnosed with erythropoietic protoporphyria (EPP). Beyond its established product, Clinuvel's development pipeline encompasses several other promising compounds. These include CUV9900, an alpha-melanocyte stimulating hor ... mone analogue; Parvysmelanotide (VLRX001), which is recognized for its ability to provoke heightened and sustained cellular activity; and PRÉNUMBRA, an injectable liquid formulation of afamelanotide. Furthermore, Clinuvel has forged a strategic partnership with HK Winhealth Pharma Group Co. Limited. This collaboration aims to provide SCENESSE to EPP patients in the People's Republic of China via a dedicated named patient program.
Frequently Asked Questions
-
What is the current Clinuvel Pharmaceuticals Limited (CLVLF) stock price?
-
Clinuvel Pharmaceuticals Limited(OTC:CLVLF) stock price is $6.1 in the last trading session. During the trading session, CLVLF stock reached the peak price of $8.6 while $6.1 was the lowest point it dropped to. The percentage change in CLVLF stock occurred in the recent session was 0.0% while the dollar amount for the price change in CLVLF stock was $0.
-
CLVLF's industry and sector of operation?
-
The OTC listed CLVLF is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of CLVLF?
-
Azza Hamila | Head of Quality Assurance & Drug Safety
Dennis J. Wright | Chief Scientific Officer
Emilie Rodenburger | Director of Global Clinical Affairs
Linda Teng | Director of North American Operations
Philippe Jacques Wolgen | Chief Executive Officer, MD & Director -
How many employees does CLVLF have?
-
Number of CLVLF employees currently stands at 109. CLVLF operates from 535 Bourke Street, Melbourne, VIC 3000, AU.
-
Link for CLVLF official website?
-
Official Website of CLVLF is: https://www.clinuvel.com
-
How do I contact CLVLF?
-
CLVLF could be contacted at phone #61 3 9660 4900 and can also be accessed through its website. CLVLF operates from 535 Bourke Street, Melbourne, VIC 3000, AU.
-
How many shares of CLVLF are traded daily?
-
The average number of CLVLF shares traded daily for last 3 months was 159.
-
What is the market cap of CLVLF currently?
-
The market value of CLVLF currently stands at $307.51M with its latest stock price at $6.1